Please see below for all latest press releases and company news.

Waterford's EirGen Pharma partners with South African firm 7/11/2011

EirGen Pharma, currently on an Enterprise Ireland trade mission to South Africa, has secured a significant partnership agreement with South African pharmaceuticals company Equity Pharmaceuticals to develop and commercially supply five oncology products from its Waterford facility.

This week's Enterprise Ireland trade mission to South Africa, where 28 Irish firms are holding meetings with their South African counterparts, is being led by Ireland's Minister of State for Trade and Development, Jan O'Sullivan, TD.

The deal size between EirGen Pharma and Equity Pharmaceuticals is €3m per annum, based on an anticipated 20pc market share of the €15m market for this portfolio of oncology products, said Enterprise Ireland today.

Tom Brennan and Patsy Carney co-founded EirGen Pharma in 2005. It employs 45 people at its plant in Waterford, which focuses on the development and supply of niche highly potent drugs typically used in cancer treatment.

Innovative Irish firms make their marks internationally O'Sullivan said the partnership is another "major win" for an Irish company that has carved out a successful business in international markets.

"EirGen Pharma's success confirms that ambitious, innovative Irish companies are highly regarded for their quality of product and service, innovative capabilities and customer focus. Irish companies are winning more and more business in South Africa, and the potential for continued growth is strong. Enterprise Ireland is working with them in the region to strengthen their business links, develop strategic partnerships and win new business contracts," added O'Sullivan. Speaking after the announcement, Carney said the company was "delighted" to have secured this agreement with one of South Africa's fastest-growing pharmaceuticals companies.

"EirGen and Equity plan to take a significant share of the current market of €15m for these products. We also see further potential in our partnership in the future as we are currently jointly evaluating four other additional oncology products for potential entry to the South Africa and other markets in the region," he added. Johann Willemse, CEO of Equity Pharmaceuticals, said the partnership was a reflection of the company's commitment to bring therapeutically important, high-value products to the South African market.

Enterprise Ireland's head of International Sales and Partnering, Kevin Sherry, who is accompanying O'Sullivan on the visit, said the partnership with Equity Pharmaceuticals is a very significant one for EirGen.

"South Africa is recognised as the regional economic powerhouse in sub-Saharan Africa. It is a growing market where an increasing number of Irish companies are establishing a foothold and securing sales. This trade mission is about building on that success, assisting more Irish companies to win more business and thereby increase exports, which will directly sustain and create jobs in Ireland."

LINK Healthcare announces licence deal for Relistor®

LINK Healthcare today announced it had been granted a licence to market Relistor® (methylnaltrexone) in Australia, New Zealand, South Africa and Asia from Salix Pharmaceuticals, Inc. of North Carolina, USA.  Relistor subcutaneous injection is indicated for the treatment of opioid-induced constipation (OIC) in patients with advanced illness who are receiving palliative care, when response to laxative therapy has not been sufficient.

For full article details, please download the PDF.

ANAPEN 500μg receives marketing approval

LINK Pharma has received marketing approval in both Australia and New Zealand for
"ANAPEN 500," a 500 microgram adrenaline auto-injector. "ANAPEN 500" is approved for
adults with a mean body weight of 60kg or more, or adults at high risk of severe
anaphylaxis for whom a 300 microgram dose may not be sufficient. Australian and
International resuscitation guidelines recommend an initial treatment of 500 micrograms
adrenaline as a front line treatment for all patients suffering from anaphylaxis with a body
weight of greater than 60kg. Up until now, no auto-injector product has met this need.
ANAPEN 500 compliments LINK's currently marketed ANAPEN adrenaline auto-injector
range, which deliver either 150μg or 300μg, and are PBS listed. LINK Pharma plans a
regional launch for "ANAPEN 500" in the coming months.

LINK Pharma adds ampoules to adrenaline portfolio

LINK Pharma has acquired the range of adrenaline products previously sold by Astra
Zeneca Australia. The registrations for both 1:1000 and 1:10,000 strength ampoules have
been recently transferred. This range is a perfect fit with LINK'S ANAPEN adrenaline
auto-injector, which was launched in 2010.

Gentium Appoints LINK Pharmaceuticals as Exclusive Distributor of Defibrotide in Australia and New Zealand

VILLA GUARDIA (COMO), Italy, June 15, 2011, (GLOBE NEWSWIRE) -- Gentium S.p.A.
(NASDAQ: GENT) announced the appointment of LINK Pharmaceuticals as exclusive distributor of Defibrotide in Australia and New Zealand. Under the terms of the agreement, LINK will be responsible for managing named patient requests.

For full article details, please download the PDF.

Stallergenes obtains a marketing authorisation for oralair® in Australia

Antony (France), 18 May 2011 - Stallergenes S.A. has announced that the Australian health authority, the Therapeutic Goods Administration (TGA), has approved the grass pollen sublingual immunotherapy tablet, Oralair® in adult and pediatric indications.

A proven ability to build and sustain an agile sales and marketing solution is ideally suited to specialist pharmaceuticals and medical devices, which are marketed to a targeted group of medical specialists.

For full article details, please download the PDF.

Stallergenes - LINK Pharmaceuticals partnership in Australia

Stallergenes and LINK are pleased to announce the reinforcement of their partnership for the Australian market. Stallergenes has recently created a dedicated Australian affiliate company to work alongside LINK, providing management, medical and marketing support to answer the specific needs of allergy clinicians and patients with allergies.

For full article details, please download the PDF.

Anapen® Registered for Marketing in Australia

SYDNEY, NSW, OCTOBER 28, 2008. LINK Pharma, a specialist Australian-owned pharmaceutical company, is pleased to announce that the Anapen® adrenaline auto-injector has been approved for marketing in Australia. LINK has been working towards providing an alternative adrenaline auto-injector device for the many Australians who may be at risk of anaphylaxis. The registration of Anapen® in Australia brings LINK Pharma a step closer to this goal. The launch of Anapen® represents the first stage in the roll out of a new LINK Immunology Business Unit with further product launches planned. The recently announced distribution partnership with the French Immunotherapy company Stallergenes will be included in this Business Unit and will commence operation on 1st December 2008.

Anapen® has been successfully launched in 14 countries in Europe and North America. LINK is proud to be the first company to launch Anapen® in the Southern Hemisphere. LINK will be launching both Anapen® 300µg and Anapen® Junior 150µg early in 2009 and the company is looking to work closely with ASCIA, the immunology profession, Anaphylaxis Australia and other relevant stakeholders to ensure the product is marketed within a strong framework of patient education.

LINK's new Immunology Business Unit is headed by Sales & Marketing Manager, Mr. Kenneth Allan with Ms. Sabrina de Miranda stepping into the Product Management role. Healthcare providers can obtain further information on Anapen,® it's mechanism of action and the Anapen® training device at www.analert.com.au

LINK Pharmaceuticals: second major acquisition in 2008 (25/09/08)

LINK Pharmaceuticals today announced a second major acquisition for 2008 with the transfer of the former Novartis products Apresoline, Deseril and Hygroton.

This transfer is an extension of LINK’s on-going partnership with the UK company Amdipharm.

Amdipharm recently completed the acquisition of these products from Novartis for several international markets and LINK will market them in Australia on Amdipharm’s behalf.

LINK Pharmaceuticals Acquisition (20/05/08)

LINK Pharmaceuticals today announced the transfer of the Akineton, Erythocin IV and the EES (erythromycin) product range from Abbott Australia.
This transfer is the result of LINK’s on-going partnership with the UK company Amdipharm.
Amdipharm recently completed the acquisition of these products from Abbott for several international markets and LINK will market them in Australia on Amdipharm’s behalf.

Zostrix on the Shelves. 1 July 2007

On 1st July 2007 the big three pharmaceutical wholesalers took stock of both Zostrix and Zostrix HP. As a result retail pharmacies should have stock soon after that date. This is good news for those suffering the pain associate with osteoarthritis, diabetic neuropathy and post-herpetic neuralgia.

ZOSTRIX is registered by the Australian authorities in two strengths for the treatment of pain.  The 0.025% cream is approved for pain associated with osteoarthritis and the 0.075% formulation is approved for the relief of neuropathic pain.

LINK Pharmaceuticals’ Managing Director Mr. John Bacon commented that “ZOSTRIX is a highly effective treatment with good clinical evidence of efficacy.  The side effect profile is excellent and we expect the product to be an important part of our growing portfolio.” For more information, visit www.zostrix.com.au

Naprosyn Suspension Re-listed by PBS. 18th January 2006

On April 1st 2006 patients will have access to the liquid formulation of Naprosyn (naproxen) through the Pharmaceutical Benefits Scheme.

This completes a two year joint project between LINK Pharmaceuticals and Roche Products to secure the long-term supply of this product in Australia for the treatment of chronic arthropathies and bone pain for patients unable to take solid forms of NSAIDS.

Moving ahead, Roche will continue to market solid Naprosyn formulations and LINK will distribute and co-promote the more specialist liquid formulation.

For further information please contact the Customer Service Department of LINK Pharmaceuticals.

LINK Completes Second Acquisition From Pfizer. 12th July 2005

LINK Pharmaceuticals announces the acquisition of two antibiotic products from Pfizer for the territories of Australia and New Zealand. The two injectable products, colistin and chloramphenicol are both essential treatments for serious infections. While the use of chloramphenicol is now highly restrictive due to the high incidence of serious side effects, it still has an important role in the treatment of highly resistant organisms.

Colistin is an essential treatment of serious gram-negative infections, particularly Pseudomonas aeruginosa.

In announcing the acquisition, Managing Director John Bacon commented “we are pleased to complete this acquisition with Pfizer’s regional office.  Both products are a very good fit to our current range.  Chloramphenicol is quite a low volume product but it’s maintenance on the market is critically important.  Colistin is also an important antibiotic but in this case we believe it has some potential for growth.”